Pre-Made Efineptakin Alfa Biosimilar, Fusion Protein targeting IL7R fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CD127/CDW127 for drug discovery and mechanism of action (MOA) research

Pre-Made Efineptakin Alfa Biosimilar, Fusion Protein targeting IL7R fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CD127/CDW127 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efineptakin alfa A long-acting immunoglobulin (Ig) fusion protein composed of a recombinant form of the endogenous human protein interleukin-7 (rhIL-7) and fused to a hybrid Fc (hyFc) region of a human antibody, with hematopoietic and immunopotentiating activities. Upon administration of efineptakin alfa, IL-7 stimulates the proliferation, differentiation, trafficking and survival of a variety of T-cell subsets, including naive, central memory (CM), effector memory (EM), terminally differentiated effector memory (TEMRA) and natural killer (NK) T cells, and enhances T-cell-mediated anti-tumor immune responses.